RTW Biotech Opportunities Ltd
RTWFF
$1.30
-$0.03-2.26%
| Weiss Ratings | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | C | |||
| Rating Factors | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.36 | |||
| Price History | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -3.70% | |||
| 60-Day Total Return | -35.00% | |||
| 90-Day Total Return | -14.47% | |||
| Year to Date Total Return | -35.00% | |||
| 1-Year Total Return | 4.00% | |||
| 2-Year Total Return | 1.56% | |||
| 3-Year Total Return | -28.96% | |||
| 5-Year Total Return | -5.84% | |||
| 52-Week High % Change | -35.00% | |||
| 52-Week Low % Change | 8.33% | |||
| Price | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.00 | |||
| 52-Week Low Price | $1.20 | |||
| 52-Week Low Price (Date) | Mar 12, 2024 | |||
| 52-Week High Price (Date) | Nov 26, 2024 | |||
| Valuation | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 443.14M | |||
| Enterprise Value | 465.28M | |||
| Price/Earnings (TTM) | 2.62 | |||
| Earnings Per Share (TTM) | 0.50 | |||
| Earnings Per Share Growth | 8.76% | |||
| Price/Earnings To Growth | 0.30 | |||
| Price/Sales (TTM) | 84.97 | |||
| Price/Book (Q) | 0.67 | |||
| Enterprise Value/Revenue (TTM) | 93.49 | |||
| Price | $1.30 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -114.43 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 335.71M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 597 6980 | |||
| Address | 40 10th Avenue New York, NY 10014 | |||
| Website | www.rtwfunds.com/rtw-biotech-opportunities-ltd | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -81.70% | |||
| Profit Margin | 2,647.70% | |||
| Management Effectiveness | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -0.44% | |||
| Return on Equity | 25.65% | |||
| Income Statement | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | 5.16M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 5.16M | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -4.21M | |||
| Net Income (TTM) | 136.53M | |||
| Net Income Avl. to Common (TTM) | 136.53M | |||
| Total Revenue Growth (Q YOY) | 52.24% | |||
| Earnings Growth (Q YOY) | 164.15% | |||
| EPS Diluted (TTM) | 0.50 | |||
| EPS Diluted Growth (Q YOY) | 67.06% | |||
| Balance Sheet | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.76M | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 217.91M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 684.29M | |||
| Current Ratio (Q) | 2.345 | |||
| Book Value Per Share (Q) | $1.95 | |||
| Total Assets (Q) | 777.21M | |||
| Total Current Liabilities (Q) | 92.92M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 92.92M | |||
| Total Common Equity (Q) | 655.39M | |||
| Cash Flow | RTWFF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 94.99M | |||
| Net Change in Cash (TTM) | -19.62M | |||
| Levered Free Cash Flow (TTM) | -30.24M | |||
| Cash from Operations (TTM) | -114.61M | |||
